Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of addition of anti-inflammatory medication to anti-depressant medication on C-reactive protein levels in the treatment of depression

Next Previous
X
Search
Trial Profile

Effect of addition of anti-inflammatory medication to anti-depressant medication on C-reactive protein levels in the treatment of depression

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Vortioxetine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms PREDDICT

    • Most Recent Events

    • 07 Aug 2021 Primary endpoint (Change in MADRS, with a primary endpoint of proportion of study participants with a score reduction by 50% from baseline to 6 weeks (end of treatment).) has not been met. according to the results published in the European Neuropsychopharmacology.
    • 07 Aug 2021 Results published in the European Neuropsychopharmacology
    • 03 Dec 2020 Results of an analysis describing the method used in this study for switching from already (at the time of screening) taking antidepressant medication to Vortioxetine published in the International Journal of Neuropsychopharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top